, Tracking Stock Market Picks
Enter Symbol:
Ironwood Pharmaceuticals, Inc. (IRWD) [hlAlert]

up 23.07 %

Ironwood Pharmaceuticals, Inc. (IRWD) downgraded to Sell by UBS

Posted on: Wednesday,  Jan 16, 2013  8:25 AM ET by UBS

UBS rated Sell Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) on 01/16/2013, when the stock price was $13.60. Since
then, Ironwood Pharmaceuticals, Inc. has lost 18.75% as of 01/27/2016's recent price of $11.05.
If you would have followed this UBS's recommendation on IRWD, you would have gained 23.07% of your investment in 1106 days.

Ironwood Pharmaceuticals, Inc., formerly Microbia, Inc. is an entrepreneurial pharmaceutical company that discovers, develops and focuses to commercialize medicines targeting important therapeutic needs. The Company operates in two segments: human therapeutics and biomanufacturing. Its human therapeutics segment consists of the development and commercialization of its product candidates, including linaclotide. Its biomanufacturing segment consists of its ownership interest in Microbia, which focuses on building a specialty biochemicals business based on a strain-development platform.

UBS is the leading global wealth manager, a top tier investment banking and securities firm, and one of the largest global asset managers. In Switzerland, UBS is the market leader in retail and commercial banking. With headquarters in Zurich and Basel, Switzerland, UBS operates in over 50 countries and from all major international centers. UBS employs more than 80,000 people.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/16/2013 8:25 AM Sell
as of 12/13/2013
1 Week up  5.76 %
1 Month down  -11.07 %
3 Months up  20.84 %
1 YTD up  21.83 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/12/2012 11:25 AM Hold
12.97 14.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy